Current market catalysts

Why CRISPR Therapeutics Stock Rocked the Market Last Month

CRISPR Therapeutics stock surged nearly 19% in August following strong Q2 earnings. The company's approved blood disorder treatment Casgevy saw 78% quarter-over-quarter sales growth to $76 million, and the FDA approved its label expansion for pediatric patients aged 2 and older. CRISPR also received a $10 million upfront payment from a licensing deal, significantly boosting revenue to $10.2 million and narrowing net losses compared to year-ago figures.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

Pomerantz LLP is investigating potential securities fraud claims against SELLAS Life Sciences Group, Inc. following reports that the company failed to timely release phase 3 clinical trial results for Galinpepimut-S after reaching a pre-specified trigger event (80th patient death). The stock declined 13.15% to $13.21 per share on August 28, 2026, following the news.

Core Scientific Director Purchases 7,000 Shares

Eric Stanton Weiss, a Director at Core Scientific, purchased 7,000 shares on August 18, 2026, at a weighted-average price of $19.19 per share, bringing his total holdings to 259,262 shares. The insider purchase signals confidence in the company's future prospects, particularly given the stock's strong 30% performance over the past 12 months and bullish analyst sentiment with 94% buy ratings and a median price target of $36.

Elastic's 2026 Outlook: AI Search Integration Fuels Enterprise Customer Retention

Elastic (ESTC) has achieved a Superscore of 80 out of 100, reflecting its successful transition to profitability in fiscal 2026 with $368 million in net income. The company's AI-driven products like Search AI and agentic workflows are driving enterprise customer retention and expansion. However, stretched valuation multiples (EV-to-EBITDA of 502x) and intense competition from hyperscalers present risks. The analyst predicts the stock could double by 2031 if the company sustains mid-teens revenue growth and pushes operating margins toward 20%.

17 Education & Technology Group Inc. Announces Second Quarter 2026 Unaudited Financial Results

17 Education & Technology Group Inc. (NASDAQ: YQ) reported Q2 2026 net revenues of RMB90.1 million, a 254.6% year-over-year increase, with gross margin expanding to 69.2%. The company achieved its first quarterly GAAP net profit of RMB1.1 million and adjusted net income of RMB4.7 million, driven by expansion of its AI-powered Yiqi Aixue consumer application and improved operational efficiency. The company maintains a strong cash position of RMB456.9 million.

Here's the One Storage Stock I'd Buy With $2,000

The AI data center boom has driven storage companies to secure multiyear contracts with locked-in pricing and volumes extending into 2027-2029. Western Digital, Seagate, and Sandisk all benefit from this demand surge, but Seagate emerges as the top pick due to its pricing locked for all of 2027 and most capacity allocated through 2028, combined with accelerating 56% year-over-year growth guidance.

Crypto Market Today, Sept. 8: Bitcoin Slides as Fed Hike Odds Pass 60%

Bitcoin fell 0.9% to $78,475 on September 8, 2026, as Federal Reserve rate hike odds exceeded 60% and a Liquid Network hack pressured sentiment. Ethereum showed resilience, declining only 0.1%, buoyed by the Ethereum Foundation's quantum readiness announcement and corporate buying. Solana fell 0.6% amid broader macro caution driven by rising oil prices and rate hike concerns.

Prediction: This AI Power Stock Will Double Revenue Before 2030. Here's the Math.

Vertiv Holdings, a provider of critical digital infrastructure for AI data centers, generated $10.2 billion in revenue in 2025 and is positioned to double that by 2030. Management targets 20-22% annual organic sales growth through 2030, with projected revenue of $26 billion. The company exited 2025 with $15 billion in backlog and faces execution risks related to capacity expansion and sustained demand as the AI infrastructure build-out matures.

17 Education & Technology Q2 Adj. EPS $0.06 Up From $(0.29) YoY, Sales $13.278M Up From $3.547M YoY

Bitcoin Braces For CPI as Oil Nears $100 and ETF Inflows Hit $3.8 Billion

Bitcoin holds near $79,000 as oil and yields rise ahead of U.S. inflation data, while $3.8 billion in ETF inflows provides strong support.

8-K/A filing — Granite Ridge Resources, Inc. (GRNT)

Filed: 2026-09-09 AccNo: 0001928446-26-000062 Size: 141 KB Item 5.07: Submission of Matters to a Vote of Security Holders

8-K filing — Evommune, Inc. (EVMN)

Filed: 2026-09-09 AccNo: 0001193125-26-385430 Size: 1 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Full Transcript: Mission Produce Q3 2026 Earnings Call

Mission Produce (NASDAQ:AVO) held its third-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial

Here’s How Much You Would Have Made Owning Eli Lilly Stock In The Last 10 Years

Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 16.85% on an annualized basis producing an average annual return of 30.5%. Currently, Eli Lilly has a market capitalization of $1.00 trillion.

8-K filing — FOOD CULTURE INC.

Filed: 2026-09-09 AccNo: 0001477932-26-005464 Size: 151 KB Item 8.01: Other Events

Elon Musk Documentary Gets Perfect Score After Film Festival Premiere, Trailer Shows Criticism of ‘Real-Life Iron Man’

A film about Elon Musk that the billionaire doesn't want people to see is getting positive reviews after its world premiere.

Evommune Reveals Top-Line Results From EVO756 Phase 2b Trial In Moderate-To-Severe Atopic Dermatitis; Says Trial Did Not Meet The Primary Endpoint Of Percent Change In Eczema Area And Severity Index Score From Baseline At Week 12; EVO756 Was Generally Well Tolerated; To Continue Phase 2b Development Of EVO756 In Migraine Prophylaxis; Will Not Advance EVO756 In Atopic Dermatitis

Here's How Much $100 Invested In Linde 10 Years Ago Would Be Worth Today

Linde (NASDAQ:LIN) has outperformed the market over the past 10 years by 1.14% on an annualized basis producing an average annual return of 14.78%. Currently, Linde has a market capitalization of $217.97 billion.

8-K filing — TELEFLEX INC (TFX)

Filed: 2026-09-09 AccNo: 0000096943-26-000101 Size: 174 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Buyout Debt Is Surging to Levels Not Seen Since Before the Financial Crisis

Bankers are looking to sell off approximately $138 billion of buyout debt in the coming months, according to JPMorgan.

8-K filing — X4 Pharmaceuticals, Inc (XFOR)

Filed: 2026-09-09 AccNo: 0001501697-26-000076 Size: 2 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

8-K filing — Bit Digital, Inc (BTBT)

Filed: 2026-09-09 AccNo: 0001213900-26-098132 Size: 18 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much Today

Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 15 years by 4.89% on an annualized basis producing an average annual return of 18.08%. Currently, Royalty Pharma has a market capitalization of

'Blackstone’s Head of Real Estate Is Leaving the Firm'- WSJ

QUICK SPARK: LIV Golf’s $1 Billion Debt Problem Triggers Bankruptcy Filing

LIV Golf’s push to bring outside investors into its teams has taken on new urgency after the league filed for Chapter 11 bankruptcy.

8-K filing — Sound Point Meridian Capital, Inc. (SPMA)

Filed: 2026-09-08 AccNo: 0001829126-26-009903 Size: 253 KB Item 8.01: Other Events

8-K/A filing — Vivos Therapeutics, Inc. (VVOS)

Filed: 2026-09-08 AccNo: 0001493152-26-041807 Size: 241 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits

8-K filing — Ellington Credit Co (ELLA)

Filed: 2026-09-08 AccNo: 0001628280-26-060947 Size: 179 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

8-K filing — Chime Financial, Inc. (CHYM)

Filed: 2026-09-08 AccNo: 0001193125-26-385383 Size: 776 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

8-K filing — Ellington Financial Inc. (EFC-PC)

Filed: 2026-09-08 AccNo: 0001628280-26-060946 Size: 211 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits